Nynomic AG (M7U) - Total Liabilities
Based on the latest financial reports, Nynomic AG (M7U) has total liabilities worth €32.87 Million EUR (≈ $38.43 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Nynomic AG to see how much of total assets are deployed in long-term investments.
Nynomic AG - Total Liabilities Trend (2013–2024)
This chart illustrates how Nynomic AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Nynomic AG.
Nynomic AG Competitors by Total Liabilities
The table below lists competitors of Nynomic AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UNIBEP S.A.
WAR:UNI
|
Poland | zł1.64 Billion |
|
Davicom Semiconductor Inc
TW:3094
|
Taiwan | NT$104.36 Million |
|
Hyosung Chemical Corp
KO:298000
|
Korea | ₩1.95 Trillion |
|
YESASIA HOLDINGS LTD
F:4CM
|
Germany | €83.70 Million |
|
Vytrus Biotech S.A.
MC:VYT
|
Spain | €4.35 Million |
|
Spruce Biosciences, Inc. Common Stock
NASDAQ:SPRB
|
USA | $19.12 Million |
|
DAE HWA Pharmaceutical Co. Ltd
KQ:067080
|
Korea | ₩134.61 Billion |
|
Samindo Resources Tbk
JK:MYOH
|
Indonesia | Rp43.11 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Nynomic AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Nynomic AG to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nynomic AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nynomic AG (2013–2024)
The table below shows the annual total liabilities of Nynomic AG from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €36.55 Million ≈ $42.73 Million |
-23.18% |
| 2023-12-31 | €47.58 Million ≈ $55.62 Million |
-22.53% |
| 2022-12-31 | €61.42 Million ≈ $71.80 Million |
+14.18% |
| 2021-12-31 | €53.79 Million ≈ $62.88 Million |
+3.36% |
| 2020-12-31 | €52.04 Million ≈ $60.84 Million |
+12.20% |
| 2019-12-31 | €46.38 Million ≈ $54.23 Million |
+28.13% |
| 2018-12-31 | €36.20 Million ≈ $42.32 Million |
+11.69% |
| 2017-12-31 | €32.41 Million ≈ $37.89 Million |
+115.27% |
| 2016-12-31 | €15.06 Million ≈ $17.60 Million |
-1.71% |
| 2015-12-31 | €15.32 Million ≈ $17.91 Million |
-11.79% |
| 2014-12-31 | €17.36 Million ≈ $20.30 Million |
-11.85% |
| 2013-12-31 | €19.70 Million ≈ $23.03 Million |
-- |
About Nynomic AG
Nynomic AG, together with its subsidiaries, manufactures and sells products for permanent, non-contact, and non-destructive optical measurement technology. The company also supplies customized system solutions in the areas of control engineering, sensor technology, and laboratory automation or spectrometry; components and systems for industrial optical spectroscopy, including UV-VIS-NIR and Raman… Read more